【摘要】 目的 探究采用利拉鲁肽与甲双胍联合治疗2型糖尿病患者后临床效果及药学分析。方法 选取2021年10月—2023年10月泰兴市人民医院收治的2型糖尿病患者80例为研究对象，采用随机数表法分为对照组、观察组，每组40例。对照组采取二甲双胍治疗，观察组在对照组基础上采取利拉鲁肽治疗，对比两组患者血糖水平、体质指数（body mass index, BMI）、治疗效果、不良反应。结果 观察组空腹血糖水平（fasting plasma glucose, FPG）、餐后2 h血糖水平（2-hour fasting blood glucose, 2 hPG）、糖化血红蛋白（glycosylated hemoglobin A1C, HbA1c）为（5.24±1.26）mmol/L、（8.04±1.41）mmol/L、（7.03±1.31）%均低于对照组，差异有统计学意义（P均<0.05）；观察组BMI低于对照组，差异有统计学意义（P<0.05）；观察组治疗效果95.00%高于对照组，差异有统计学意义（P<0.05）；两组不良反应发生率比较，差异无统计学意义（P>0.05）。结论 在对2型糖尿病患者进行治疗时，选择利拉鲁肽联合二甲双胍治疗方式，疗效明显，有利于改善血糖水平和BMI，整体安全性较高。更多还原

【Abstract】 Objective To explore the clinical effect and pharmaceutical analysis of liraglutide combined with metformin in the treatment of type 2 diabetes. Methods 80 cases of type 2 diabetes patients admitted to Taixing People’s Hospital from October 2021 to October 2023 were selected as the study subjects, and were divided into the control group and the observation group using the random number table method, with 40 cases in each group. The control group was treated with metformin, and the observation group was treated with liraglutide on the basis of the control group. Compared the blood glucose level, body mass index(BMI), treatment effect, and adverse reactions between the two groups. Results The fasting plasma glucose level(FPG), 2-hour fasting blood glucose(2 hPG) and glycosylated Hemoglobin type A1C(HbA1c) in the observation group were(5.24±1.26) mmol/L,(8.04±1.41) mmol/L and(7.03±1.31)%, respectively, lower than those in the control group, and the differences were statistically significant(all P<0.05). BMI of observation group was lower than that of control group, and the difference was statistically significant(P<0.05). The treatment effect of observation group was 95.00% higher than that of control group, and the difference was statistically significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion In the treatment of patients with type 2 diabetes, liraglutide combined with metformin has obvious efficacy, is conducive to improving blood glucose level and BMI, and has high overall safety.更多还原